YY-20394

YY-20394 (Linperlisib, PI3Kδ-IN-2) is a potent and selective PI3Kδ inhibitor. YY-20394 significantly inhibited primary tumor growth in immune-competent mice with 4T1 and CT26 tumors, as well as 4T1 lung metastasis with dose dependency. YY-20394 significantly inhibited T cell differentiation into Treg both in mouse splenocyte and in human primary CD4+ T cells, and was especially potent inhibiting their IL-10 secretion in vitro.


Cat. No.: EX-A1436	Purity: >98%

	Chemical structure of YY-20394

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	382	In-stock
250mg	750	In-stock
500mg	1198	In-stock
1g	1885	In-stock
2g	2998	In-stock
5g	5620	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	Linperlisib
Synonyms 2	PI3Kδ-IN-2
CAS No.	1702816-75-8
Purity	>98%
Formula	C28H37FN6O5S
Mol Weight	588.694
State	solid powder
Solubility	soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. WO 2015055071 A1 [2]. Jiang B, Qi J, Song Y, et al. Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies. J Hematol Oncol. 2021;14(1):130. Published 2021 Aug 23. doi:10.1186/s13045-021-01140-z [3]. Wang T, Sun X, Qiu L, et al. The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial. Clin Cancer Res. 2023;29(8):1440-1449. doi:10.1158/1078-0432.CCR-22-2939
CoA	CoA of YY-20394

Smiles:	COC1=C(NS(C)(=O)=O)C=C(C=N1)C1=NC(=NC2=C1C=C(F)C=C2CN1CCC(CC1)C(C)(C)O)N1CCOCC1


		Search